• Explore /
  • Poster
  • / GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.

GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.

Abstract Poster

Authors

null

Juan Manuel Sepúlveda

12 de Octubre Universitary Hospital, Madrid, Spain

Juan Manuel Sepúlveda , M. Angeles Vaz , Aurelio Hernandez-Lain , Miquel Gil , Pilar Sanhez , Ramos Ana , Oscar Gallego , Gaspar Reynes , Maria Victoria Bolós , Raquel Luque , M. Quindos , Maria Martinez Garcia , Pedro Pérez Segura , Manuel Benavides , Carmen Balañá

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS2110)

DOI

10.1200/jco.2014.32.15_suppl.tps2110

Abstract #

TPS2110

Poster Bd #

70B

Abstract Disclosures

Similar Posters

First Author: Mark Rosenthal

First Author: Jaime Feliu

First Author: Ulrich Keilholz

First Author: Radoslav Chekerov